Cellceutix Corporation, a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, provided additional research data on Kevetrin, its’ p53 breakthrough anti-cancer compound.
Kevetrin was studied as combination therapy with radiation to treat human head and neck cancer lines implanted in animals. While tumours treated with Kevetrin or radiation alone each showed significant anti-tumour activity, tumours treated with Kevetrin followed by radiation one week later demonstrated superior results in controlling tumour size. Since the sequence of Kevetrin followed by radiation outpaced the reverse (radiation then Kevetrin), Kevetrin may be acting as a “radiosensitizer”, a term used to describe sensitization of tumour cells to radiation at the cellular level.
Dr Krishna Menon, chief scientific officer of Cellceutix, commented, “Our research to date has shown the potential of Kevetrin as a stand-alone therapy. This additional data demonstrates its value as a combination therapy. We believe the radiosensitizer capacity of Kevetrin is once again attributable to its interaction with p53. The data that we have collected in our pre-clinical studies on Kevetrin gives me great hope that Cellceutix is developing a drug that one day will have a major impact on cancer treatments.”
Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism.